$MNKD News

MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of Afrezza

MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With Diabetes

MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8

RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75

MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10

Mizuho Maintains Outperform on MannKind, Lowers Price Target to $7

HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $10

MannKind Corporation 2026 Q1 - Results - Earnings Call Presentation

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress

MannKind Q1 Adj. EPS $(0.02) Misses $(0.00) Estimate, Sales $90.171M Miss $106.555M Estimate

Undervalued Small Caps With Insider Buying To Consider In May 2026

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $8